Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
10.1186/s40880-016-0162-7
- Author:
A.Kuczynski ELIZABETH
1
;
S.Kerbel ROBERT
Author Information
1. Sunnybrook Research Institute
- Keywords:
Vessel co-option;
Non-angiogenic;
Resistance;
Sorafenib;
Hepatocellular carcinoma
- From:Chinese Journal of Cancer
2016;35(12):641-644
- CountryChina
- Language:Chinese
-
Abstract:
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well under-stood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma” in theJournal of the National Cancer Institute, providing a potential explanation for this limited beneift. We found that in mice bearing HCCs that had acquired resistance to sorafenib, tumors had switched from using angiogenesis for growth to co-opting the liver vas-culature by becoming more invasive. Accumulating evidence suggests that many human tumor types may use vessel co-option, which has profound implications for the use of anti-angiogenic agents for cancer treatment.
